Zhiqi Hao

Dr. Zhiqi Hao

Analytical Development and Quality Control, Genentech Inc, South San Francisco, California, USA
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
ZHZhiqi Hao
Zhiqi Hao
BMBenjamin Moore
Benjamin Moore
CRChengfeng Ren
Chengfeng Ren
MSMonica Sadek
Monica Sadek
FMFrank Macchi
Frank Macchi
CYChristopher Yu
Christopher Yu

11 September 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ZHZhiqi Hao
Zhiqi Hao
CYChristopher Yu
Christopher Yu
ABAnja Bathke
Anja Bathke
JYJack Yim
Jack Yim
ABAlexander Buettner
Alexander Buettner
YYYi Yang
Yi Yang
The increasing complexity of modern protein therapeutics and the demand for faster development of new therapeutics require not only advanced analytical tools that provide in-depth understanding of the product quality attributes (PQAs) that are crucial for safety and efficacy but also the implementation of a control strategy to ensure that the released drug product meets the desired quality profile. The multi-attribute method (MAM), a liquid chromatography–mass spectrometry (LC-MS) approach, has emerged as a transformative solution that provides site-specific monitoring of multiple critical quality attributes (CQAs) in a single workflow, replacing several conventional profile-based assays. The MAM achieves comprehensive quality oversight through two primary mechanisms: targeted attribute quantitation (TAQ) for the simultaneous quantification of predefined known modifications, and new peak detection (NPD) for identifying unforeseen impurities, thereby establishing a robust, “double-layered” control strategy. This article reviews the practical challenges and current industry practices for successfully implementing the MAM within current good manufacturing practice (cGMP) environments. The successful transition of the MAM from a specialized characterization tool to a validated quality control (QC) cornerstone relies on a framework built upon four foundational pillars: stringent instrument qualification paired with compliance-ready informatics, proactive and strictly scheduled instrument maintenance, rigorous system suitability testing (SST), and phase-appropriate method validation and transfer. The challenges of global method transfer and the solutions to mitigate inter-laboratory variability are discussed. Finally, the review explores the emerging trends shaping the future of the MAM in QC and the critical role of the MAM in facilitating real-time release testing (RTRT) in next-generation autonomous manufacturing.

1 January 2015 in ACS Symposium Series
Verified
Book Chapter
Closed access
ZHZhiqi Hao
Zhiqi Hao
TZTerry Zhang
Terry Zhang
YXYue Xuan
Yue Xuan
HWHongxia Wang
Hongxia Wang
JQJie Qian
Jie Qian
AMAlexander Makarov
Alexander Makarov

9 October 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
KCKelvin Chang
Kelvin Chang
QCQinjingwen Cao
Qinjingwen Cao
CCChuntian Cai
Chuntian Cai
WCWayman Chan
Wayman Chan
ZHZhiqi Hao
Zhiqi Hao
FYFeng Yang
Feng Yang
Background/Objectives: The Multi-Attribute Method (MAM) uses LC-MS peptide mapping for targeted attribute quantitation (TAQ) and untargeted New Peak Detection (NPD) in product quality monitoring and quality control of biotherapeutics. As automated liquid handling systems are adopted, data demonstrating similar performance for both TAQ and NPD are essential to implement an automatic sample preparation workflow to fully achieve MAM capabilities. This study compares manual versus automated sample preparation workflows for both TAQ and NPD. Methods: Peptide mapping sample preparation was performed manually and on an automated liquid handling system. TAQ was evaluated using a reference monoclonal antibody (mAb1) while NPD was assessed by spiking a second monoclonal antibody (mAb2) into mAb1 (0.5–2% w/w relative abundance). NPD specificity and sensitivity were qualified using a product-specific peptide library, multiple bracketing comparisons, and a statistically derived Fold Change Detection (FCD) threshold. Results: For TAQ, the automated workflow demonstrated comparable performance to the manual method, with minimal quantitative differences and high reproducibility across 28 monitored product quality attributes. For NPD, all expected mAb2 peptides were detected with no false positives at each spike level. No new peaks were observed when comparing bracketing unspiked mAb1 samples, confirming specificity for NPD. Conclusions: The results demonstrate that automated sample preparation yields consistent TAQ and NPD data compared to manual methods and can be used for routine product quality monitoring.